Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) has improved survival with tyrosine kinase inhibitors (TKIs).
• A notable percentage of CML patients exhibit suboptimal responses to imatinib and second-generation TKIs (2GTKIs).
• Treatment failure in CML can stem from resistance, intolerance, or nonadherence, necessitating careful evaluation.

Purpose of the Study:

• To offer practical guidance for selecting optimal treatments in CML patients with inadequate responses to prior therapies.
• To differentiate between causes of treatment failure, including resistance, intolerance, and nonadherence.
• To review available treatment options, such as alternative 2GTKIs and ponatinib.

Main Methods:

• Review of clinical practice guidelines and published literature on CML treatment.
• Analysis of factors influencing treatment selection for patients with inadequate response to TKIs.
• Case scenario discussions to illustrate decision-making processes.

Main Results:

• Alternative 2GTKIs and ponatinib are viable options for CML patients failing initial TKI therapies.
• Accurate diagnosis of resistance versus intolerance/nonadherence is crucial for effective treatment switching.
• Personalized treatment selection based on individual patient factors and failure mechanisms is recommended.

Conclusions:

• Optimal management of CML requires a nuanced approach to treatment selection after failure of initial TKIs.
• Understanding the specific reason for treatment failure is paramount for successful therapeutic intervention.
• This review provides a framework for clinicians to navigate complex treatment decisions in CML management.